Form 4: CareDx Director Peter Maag Executes Stock Option and Sells Shares Under 10b5-1 Plan

CareDx director Peter Maag exercised stock options and sold 5,000 shares of common stock on November 26, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Peter Maag, a director at CareDx, Inc., executed a stock option to acquire 5,000 shares of common stock at a price of $12.24 per share on November 26, 2024.
• On the same day, Mr. Maag sold 5,000 shares of CareDx common stock at a price of $25 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 21, 2024.
• Following these transactions, Mr. Maag directly owns 330,024 shares of CareDx common stock and 1,250 stock options.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative in itself.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a common practice for insiders to avoid accusations of trading on non-public information.

Risks

• The sale of shares by a director could be perceived negatively by the market, although it is part of a pre-planned strategy.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. The use of a 10b5-1 plan is a standard practice to manage insider transactions.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives and directors at publicly traded companies, such as those in the biotechnology and healthcare sectors, to manage their stock transactions.
• Companies like Exact Sciences (EXAS) and Illumina (ILMN) also have executives who utilize 10b5-1 plans for their stock transactions.
• The reported transaction is typical for directors who receive stock options as part of their compensation.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, but the pre-planned nature of the transaction mitigates this.

Key Dates

Keywords

CareDx, Peter Maag, stock options, share sale, Rule 10b5-1, insider trading, director, CDNA